HOME >> MEDICINE >> NEWS
Melanoma research receives a massive funding boost

NSW cancer researchers from the Sydney Melanoma Unit have received over $11 million to advance their world-leading research into the diagnosis and treatment of melanoma.

Australians have the highest rate of melanoma in the world, with incidence levels up to four times higher than the US and the UK, and up to ten times higher than most other countries.

Whilst it is the third most common cancer in Australia, it has proved to be one of the most difficult to manage. It most commonly affects those in the 30-45 year age group - people in the prime of their life- yet standard cancer treatments are often ineffective.

The Sydney Melanoma Unit is a group of cancer researchers and clinicians drawn from Westmead Millennium Institute, Newcastle Mater and Royal Prince Alfred Hospitals. It runs the largest melanoma treatment centre in the world, and with associated expertise in molecular diagnosis and treatment, provides our best hope for improving outcomes in people who develop, or are at risk of developing, melanoma.

This research group was recently recognised with a $3.75 million Program Grant from the Cancer Institute NSW. Today the Hon Tony Abbott, Commonwealth Minister for Health, announced that the Unit has also been awarded a prestigious National Health and Medical Research Council Program Grant, providing a further $7.8 million to support its vital research.

"Melanoma cells that have spread from their site of origin are notorious for being resistant to cancer treatment such as chemotherapy and radiotherapy" says Professor Richard Kefford, Chief Investigator of the successful Sydney Melanoma Unit NHMRC grant and researcher at Westmead Millennium Institute.

"These funds will allow us to progress our research into the molecular factors that determine an individual's risk of melanoma, so that we can identify the type of melanoma they have and how that disease will respond to treatments. We can then create more effective treatme
'"/>

Contact: Gayle McNaught
gayle_mcnaught@wmi.usyd.edu.au
61-298-459-009
Research Australia
6-Jul-2005


Page: 1 2

Related medicine news :

1. Summer update: Melanoma research progress suggests optimism for future cures
2. Melanoma vaccine strategy shows promise in laboratory experiments
3. Melanoma risk only partially associated vith exposure to UVB from sunlight
4. 1 of 2 pediatric kidney disease research centers in world established
5. Stanford researchers find culprit in aging muscles that heal poorly
6. UCLA researchers awarded $9M contract for study identifiying antibiotic treatment for MRSA
7. Indiana University Imaging Center receives $6M grant for kidney research
8. Penn researchers discover novel pathway for increasing good cholesterol
9. New research discovers independent brain networks control human walking
10. Theory of facial aging gets a facelift from UT Southwestern researchers
11. Sports concussion research using fMRI provides insight for safe return-to-play decisions

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Melanoma research receives massive funding boost

(Date:10/20/2014)... 20, 2014 With a mere 19 ... Crist made a brief fundraising stop at the ... , Fresh from a debate last night with his ... stage for the first seven minutes because Crist had ... described the incident in one word: "weird." , Before ...
(Date:10/20/2014)... 2014 ASCNYC (ascnyc.org) is a ... New Yorkers living with HIV/AIDS and other chronic ... recovery and self-sufficiency. Each year, ASCNYC spotlights selected ... through their tireless efforts. , Savills Studley ... has been selected as this year’s honoree for ...
(Date:10/20/2014)... IN (PRWEB) October 20, 2014 ... Start, a secure cloud solution that enables healthcare ... of the ultimate healthcare-specific customer relationship management (“CRM”) ... meet the unique needs of the healthcare industry, ... experience for providers and patients by combining healthcare ...
(Date:10/20/2014)... (PRWEB) October 20, 2014 My Clients ... management software application. The new module enables easy ... receive full life-cycle quality care. , This application allows ... within their practice, attach a to-do item to a ... and even set up reoccurring reminders for follow-ups. ...
(Date:10/20/2014)... 20, 2014 Myoderm ... Assistant Director of their CentralSource service. ... the innovative turnkey drug sourcing, distribution, and management ... over 12 years of industry experience, in both ... the peak of their international success to help ...
Breaking Medicine News(10 mins):Health News:At Crist Fundraiser, Dan Newlin Says, "No More Robert Germans," Will Seek Changes to Florida Missing Persons Law 2Health News:At Crist Fundraiser, Dan Newlin Says, "No More Robert Germans," Will Seek Changes to Florida Missing Persons Law 3Health News:Savills Studley's Marc Shapses To Be Honored as 2014 "Positive Changemaker" by ASCNYC 2Health News:Savills Studley's Marc Shapses To Be Honored as 2014 "Positive Changemaker" by ASCNYC 3Health News:Healthcare Relationship Management (HRM) Leader hc1.com® Launches hc1® Quick Start™ 2Health News:My Clients Plus Announces New Workflow Management Software 2Health News:Myoderm Hires Matthew Voicheck to Lead Turnkey Drug Sourcing Service 2
(Date:10/17/2014)... 17, 2014 With the recent changes ... has come across several challenges in creating and ... globalization.  The Medical Affairs ... to providing benchmarking and best practices across critical ... a service composed of three stages: 1) member-driven ...
(Date:10/17/2014)... Research ... addition of the  "China Interventional Cardiovascular Device ...      (Logo: http://photos.prnewswire.com/prnh/20130307/600769) The ... China impacted by accelerated aging ... dietary habit, way of working and other ...
(Date:10/17/2014)... , October 17, 2014 Investor-Edge ... Inc. (NASDAQ: ARNA ), NPS Pharmaceuticals Inc. ... XOMA ), Momenta Pharmaceuticals Inc. (NASDAQ: ... Free research on these five companies can be accessed ... on Thursday, October 16, 2014, ended on a mixed ...
Breaking Medicine Technology:Early Key Findings from the Medical Affairs Consortium Research 2China Interventional Cardiovascular Device Industry Report 2014-2017 2China Interventional Cardiovascular Device Industry Report 2014-2017 3Biotech Equities Technical Briefing - Arena Pharma, NPS Pharma, XOMA, Momenta Pharma, and Catalyst Pharma Partners 2Biotech Equities Technical Briefing - Arena Pharma, NPS Pharma, XOMA, Momenta Pharma, and Catalyst Pharma Partners 3Biotech Equities Technical Briefing - Arena Pharma, NPS Pharma, XOMA, Momenta Pharma, and Catalyst Pharma Partners 4Biotech Equities Technical Briefing - Arena Pharma, NPS Pharma, XOMA, Momenta Pharma, and Catalyst Pharma Partners 5
Cached News: